EUVIMEDEUVIMED entdecken
Crossref

Sequential Precise Targeted Hepatitis B Virus Therapy: Hepatitis B Virus-Specific Small Interfering RNA Followed by Aggregation-Induced Emission-Photothermal Ablation Based on Macrophage Membrane-Coated Nanoplatform

Zihui Wei iD, Lixia Gao, Mengting Zheng, Xun Wang, Xinting Fu, Han Duan, Jiamei Wang, Yanqiu Wu, Fei Ma, Yunlong Zhang, Yue Jia, Qin Gu und 5 weitere

ACS Applied Bio Materials · 2026

DOI: 10.1021/acsabm.6c01518 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ACS Applied Bio Materials, 2026. Verfasst von Zihui Wei und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology, School of Public Health, Southern Medical University (Guangdong Provincial Key Laboratory of Tropical Disease Research), …. Hauptthemen laut MEDLINE: Hepatitis B virus, RNA, Small Interfering, Nanoparticles, Macrophages. Die Arbeit nennt 45 Literaturangaben. Gefördert von: Key Research and Development Program of Ningxia Hui Autonomous Region, Prevention and Control of Emerging and Major Infectious Diseases-National Science and Technology Major Project, National Natural Science Foundation of China (NSFC).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chronic hepatitis B (CHB) afflicts approximately 254 million people worldwide and is responsible for more than one million deaths annually. Intrahepatic persistence of covalently closed circular DNA (cccDNA), the episomal transcriptional template of hepatitis B virus (HBV), sustains chronic replication, blunts the efficacy of antiviral therapy, and precipitates virological relapse once treatment is discontinued. While emerging cccDNA-targeted strategies include CRISPR/Cas9-mediated cleavage and epigenetic silencing, their clinical translation is impeded by delivery inefficiency, safety concerns, and limited durability. Herein, we present a sequential nano-therapeutic platform that combines small interfering RNA (siRNA) delivery using HBV-pre-activated macrophage membranes (HMs) with photothermal therapy utilizing aggregation-induced emission (AIE) agents. In the first step, HM-coated lipid nanoparticles encapsulating siRNA (siR@HM NPs) enable virus to neutralize and hepatocyte targeted delivery via surface viral receptors, achieving efficient gene silencing. At 72 h post-administration, HM-coated PLGA nanoparticles loaded with an AIE photothermal agent (TPAT@HM NPs) are introduced, facilitating near-infrared IIb fluorescence-guided 808 nm laser ablation of residual infected cells. In a cell model of chronic HBV infection, both siR@HM NPs and TPAT@HM NPs achieved targeted delivery to infected hepatocytes. Critically, sequential administration yielded superior antiviral efficacy compared with concurrent administration or either monotherapy, leading to substantial reduction in HBsAg, HBeAg, HBV DNA, cccDNA, and pgRNA levels. Biosafety assessments confirmed negligible cytotoxicity, hemolysis, and systemic toxicity. This bionic platform integrates time-programmed virus targeting, RNA interference, and photothermal ablation. The virus-preactivated membrane coating enables dual recognition of both viral particles and infected cells, offering a precise and scalable theranostic strategy for HBV and other refractory viral infections.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hepatitis B virusRNA, Small InterferingNanoparticlesMacrophagesPhotothermal TherapyAntiviral AgentsHepatitis B, ChronicCoated Materials, BiocompatibleHumansAnimalsMaterials TestingParticle SizeSurface PropertiesMice

Stichwörter der Autor:innen

Hepatitis B virusmacrophage membranephotothermal therapysiRNA deliverytargeted therapy

Substanzen

RNA, Small InterferingAntiviral AgentsCoated Materials, Biocompatible

Autor:innen und Institutionen

  • Department of Microbiology, School of Public Health, Southern Medical University (Guangdong Provincial Key Laboratory of Tropical Disease Research), Guangzhou, Guangdong510515, China.
  • Institute for Engineering Medicine, Kunming Medical University, Kunming, Yunnan650500, China.
  • School of Laboratory Medicine and Biotechnology, Southern Medical University, Guangzhou, Guangdong510515, China.
  • School of Inspection & School of Basic Medical Sciences, Ningxia Medical University, Yinchuan, Ningxia750004, China.

ORCID-Profile: Zihui Wei, Yuhui Liao

Förderung

  • Key Research and Development Program of Ningxia Hui Autonomous Region
  • Prevention and Control of Emerging and Major Infectious Diseases-National Science and Technology Major Project
  • National Natural Science Foundation of China (NSFC)

Zitieren

APA

Wei, Z., Gao, L., Zheng, M., Wang, X., Fu, X., Duan, H., Wang, J., Wu, Y., Ma, F., Zhang, Y., Jia, Y., Gu, Q., He, C., Wang, Y., Li, B., Ma, W., & Liao, Y. (2026). Sequential Precise Targeted Hepatitis B Virus Therapy: Hepatitis B Virus-Specific Small Interfering RNA Followed by Aggregation-Induced Emission-Photothermal Ablation Based on Macrophage Membrane-Coated Nanoplatform. ACS Applied Bio Materials. https://doi.org/10.1021/acsabm.6c01518

Vancouver

Wei Z, Gao L, Zheng M, Wang X, Fu X, Duan H, et al. Sequential Precise Targeted Hepatitis B Virus Therapy: Hepatitis B Virus-Specific Small Interfering RNA Followed by Aggregation-Induced Emission-Photothermal Ablation Based on Macrophage Membrane-Coated Nanoplatform. ACS Applied Bio Materials. 2026. doi:10.1021/acsabm.6c01518

BibTeX
@article{Wei2026,
  author = {Wei, Zihui and Gao, Lixia and Zheng, Mengting and Wang, Xun and Fu, Xinting and Duan, Han and Wang, Jiamei and Wu, Yanqiu and Ma, Fei and Zhang, Yunlong and Jia, Yue and Gu, Qin and He, Changting and Wang, Yongli and Li, Bin and Ma, Weifeng and Liao, Yuhui},
  title = {Sequential Precise Targeted Hepatitis B Virus Therapy: Hepatitis B Virus-Specific Small Interfering RNA Followed by Aggregation-Induced Emission-Photothermal Ablation Based on Macrophage Membrane-Coated Nanoplatform},
  journal = {ACS Applied Bio Materials},
  year = {2026},
  doi = {10.1021/acsabm.6c01518}
}
Kostenlos starten →